Last reviewed · How we verify
A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy (Re-Spire)
A prospective randomised controlled study to evaluate outcomes of the treatment with pradaxa or warfarin for prevention of recurrent DVT in patients with angiographically confirmed acute massive pulmonary embolism undergoIng endovascular mechanical fragmentation and thrombolytic therapy. \[RE-SPIRE study\]
Details
| Lead sponsor | Meshalkin Research Institute of Pathology of Circulation |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | 2016-10 |
| Completion | 2018-06 |
Conditions
- Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
Interventions
- Dabigatran Etexilate
- Warfarin
Primary outcomes
- recurrent PE — 6 month
according to Echocardiogram, scintigraphy of the lungs - death — 6 month
Countries
Russia